Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole
Open Access
- 15 November 2018
- journal article
- editorial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 67 (10), 1610-1613
- https://doi.org/10.1093/cid/ciy406
Abstract
We retrospectively assessed breakthrough invasive fungal infections (b-IFIs) in 100 consecutive patients with leukemia receiving single-agent isavuconazole; 13 had documented b-IFIs (candidiasis in 6, mucormycosis in 4). All b-IFIs were observed in patients with prolonged neutropenia and active leukemia.Keywords
This publication has 13 references indexed in Scilit:
- Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 CoursesAntimicrobial Agents and Chemotherapy, 2017
- Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole ProphylaxisClinical Infectious Diseases, 2017
- Real-Life Use of Isavuconazole in Patients Intolerant to Other Azoles: Table 1.Clinical Infectious Diseases, 2016
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisThe Lancet Infectious Diseases, 2016
- Isavuconazole: A new Extended Spectrum Triazole for Invasive Mold DiseasesFuture Microbiology, 2015
- The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortalityJournal of Antimicrobial Chemotherapy, 2015
- Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B RegistryClinical Infectious Diseases, 2012
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium SpeciesAntimicrobial Agents and Chemotherapy, 2008
- Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving VoriconazoleClinical Infectious Diseases, 2004